Quote | TFF Pharmaceuticals Inc - Ordinary Shares (NYSE:TFFP)
Last: | $ |
---|---|
Change Percent: | -1.01% |
Open: | $5.10 |
Close: | $5.02 |
High: | $5.10 |
Low: | $5.01 |
Volume: | 7,787 |
Last Trade Date Time: | 02/12/2020 04:43:40 pm |
News | TFF Pharmaceuticals Inc - Ordinary Shares (NYSE:TFFP)
The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated In Vitro and Ex Vivo Models ...
2024-05-20 07:50:30 ET More on TFF Pharmaceuticals TFF Pharmaceuticals announces pricing of $4.8M public offering TFF Pharmaceuticals announces $1.2M registered direct offering Read the full article on Seeking Alpha For further details see: TFF Pharmaceut...
Message Board Posts | TFF Pharmaceuticals Inc - Ordinary Shares (NYSE:TFFP)
Subject | By | Source | When |
---|---|---|---|
FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) | Paullee | investorshub | 05/01/2023 4:00:16 PM |
Well. That was interesting | derkampfer | investorshub | 02/23/2023 7:10:27 AM |
Anyone here ? Terrible conf call last night | Paullee | investorshub | 02/17/2023 2:42:41 PM |
TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to | Paullee | investorshub | 11/06/2022 2:39:18 PM |
more delays, pretty ugly out there | Paullee | investorshub | 11/02/2022 3:36:16 AM |
News, Short Squeeze, Breakout and More Instantly...
TFF Pharmaceuticals Inc - Ordinary Shares Company Name:
TFFP Stock Symbol:
NYSE Market:
The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated In Vitro and Ex Vivo Models ...
FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thi...
Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial 6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional patients ha...